Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):341–348. doi: 10.1111/j.1365-2125.1986.tb05205.x

Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

N Hockings, A A Ajayi, J L Reid
PMCID: PMC1400946  PMID: 3011046

Abstract

The pharmacokinetics of angiotension converting enzyme (ACE) inhibitors enalapril (10 mg orally) and its active metabolite, enalaprilat (10 mg intravenously) were studied in nine young healthy volunteers aged 22-30 years and nine sex matched elderly subjects aged 65-73 years. After both drugs, a biexponential curve was fitted to the decline in plasma enalaprilat concentration. Area under the plasma concentration-time curve (AUC) was greater in the elderly for both drugs. Clearance (CL) and clearance/bioavailability (CL/F) were less in the elderly for enalaprilat and enalapril, respectively. There was no difference in F between young (0.62 +/- 0.16) and elderly subjects (0.61 +/- 0.15). Enalaprilat CL and enalapril CL/F were significantly and positively correlated to endogenous creatinine clearance. There was a significant difference in the weight corrected volume of distribution at steady state after enalaprilat between the young and elderly (P less than 0.02). The relationship between plasma enalaprilat concentrations and percentage ACE inhibition, using the Hill equation, showed no difference in the sensitivity to ACE inhibition between the young and the elderly group. The pharmacokinetic differences observed are likely to be related to an age dependent decline in renal function as well as changes in body composition. Kinetic differences partly explain the greater pharmacodynamic response in the elderly.

Full text

PDF
341

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajayi A. A., Hockings N., Reid J. L. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol. 1986 Apr;21(4):349–357. doi: 10.1111/j.1365-2125.1986.tb05206.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruce A., Andersson M., Arvidsson B., Isaksson B. Body composition. Prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scand J Clin Lab Invest. 1980 Sep;40(5):461–473. doi: 10.3109/00365518009101869. [DOI] [PubMed] [Google Scholar]
  3. Brunner D. B., Desponds G., Biollaz J., Keller I., Ferber F., Gavras H., Brunner H. R., Schelling J. L. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981 May;11(5):461–467. doi: 10.1111/j.1365-2125.1981.tb01151.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campbell B. C., Shepherd A. N., Elliott H. L., McLean K., Reid J. L. Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency. Br J Clin Pharmacol. 1982 May;13(5):755–757. doi: 10.1111/j.1365-2125.1982.tb01455.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dayton P. G., Israili Z. H., Perel J. M. Influence of binding on drug metabolism and distribution. Ann N Y Acad Sci. 1973 Nov 26;226:172–194. doi: 10.1111/j.1749-6632.1973.tb20480.x. [DOI] [PubMed] [Google Scholar]
  6. Forbes G. B., Reina J. C. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970 Sep;19(9):653–663. doi: 10.1016/0026-0495(70)90062-4. [DOI] [PubMed] [Google Scholar]
  7. Gomez H. J., Cirillo V. J., Jones K. H. The clinical pharmacology of enalapril. J Hypertens Suppl. 1983 Oct;1(1):65–70. [PubMed] [Google Scholar]
  8. Greenblatt D. J., Sellers E. M., Shader R. I. Drug therapy: drug disposition in old age. N Engl J Med. 1982 May 6;306(18):1081–1088. doi: 10.1056/NEJM198205063061804. [DOI] [PubMed] [Google Scholar]
  9. Hodsman G. P., Brown J. J., Davies D. L., Fraser R., Lever A. F., Morton J. J., Murray G. D., Robertson J. I. Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis. Br Med J (Clin Res Ed) 1982 Dec 11;285(6356):1697–1699. doi: 10.1136/bmj.285.6356.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jarrott B., Anderson A., Hooper R., Louis W. J. High-performance liquid chromatographic analysis of captopril in plasma. J Pharm Sci. 1981 Jun;70(6):665–667. doi: 10.1002/jps.2600700622. [DOI] [PubMed] [Google Scholar]
  11. Kawahara Y., Hisaoka M., Yamazaki Y., Inage A., Morioka T. Determination of captopril in blood and urine by high-performance liquid chromatography. Chem Pharm Bull (Tokyo) 1981 Jan;29(1):150–157. doi: 10.1248/cpb.29.150. [DOI] [PubMed] [Google Scholar]
  12. Kelman A. W., Reid J. L., Millar J. A. Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol. 1983 Apr;15(4):506–507. doi: 10.1111/j.1365-2125.1983.tb01542.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kjekshus J. K., Søyland E., Dickstein K., Abrahamsen A. M., Gundersen T. Acute and long-term response to enalapril in congestive failure. Br J Clin Pharmacol. 1984;18 (Suppl 2):169S–174S. doi: 10.1111/j.1365-2125.1984.tb02595.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kjekshus J. K., Søyland E., Dickstein K., Abrahamsen A. M., Gundersen T. Sustained haemodynamic effects of enalapril in left ventricular failure. J Hypertens Suppl. 1983 Oct;1(1):143–145. [PubMed] [Google Scholar]
  15. Klotz U. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet. 1976;1(3):204–218. doi: 10.2165/00003088-197601030-00003. [DOI] [PubMed] [Google Scholar]
  16. O'Malley K., Crooks J., Duke E., Stevenson I. H. Effect of age and sex on human drug metabolism. Br Med J. 1971 Sep 11;3(5775):607–609. doi: 10.1136/bmj.3.5775.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ramsay L. E., Tucker G. T. Clinical pharmacology: drugs and the elderly. Br Med J (Clin Res Ed) 1981 Jan 10;282(6258):125–127. doi: 10.1136/bmj.282.6258.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Staessen J., Fagard R., Lijnen P., Amery A. Captopril and agranulocytosis. Lancet. 1980 Apr 26;1(8174):926–927. doi: 10.1016/s0140-6736(80)90853-3. [DOI] [PubMed] [Google Scholar]
  19. Till A. E., Gomez H. J., Hichens M., Bolognese J. A., McNabb W. R., Brooks B. A., Noormohamed F., Lant A. F. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos. 1984 Jul-Sep;5(3):273–280. doi: 10.1002/bdd.2510050309. [DOI] [PubMed] [Google Scholar]
  20. Tocco D. J., deLuna F. A., Duncan A. E., Vassil T. C., Ulm E. H. The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos. 1982 Jan-Feb;10(1):15–19. [PubMed] [Google Scholar]
  21. Triggs E. J., Nation R. L. Pharmacokinetics in the aged: a review. J Pharmacokinet Biopharm. 1975 Dec;3(6):387–418. doi: 10.1007/BF01059473. [DOI] [PubMed] [Google Scholar]
  22. Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Vestal R. E. Drug use in the elderly: a review of problems and special considerations. Drugs. 1978 Oct;16(4):358–382. doi: 10.2165/00003495-197816040-00004. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES